文献速递银屑病与炎症性皮肤病

基于价值的银屑病治疗启动与转换医疗模式:IMPROVE 前瞻性多中心研究结果

A value-based healthcare model for initiating and switching psoriasis therapies-Results from the prospective multicentre IMPROVE study.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2023-12-14

该前瞻性非干预研究纳入 49 例 PASI≥3 且正在启动或转换治疗的银屑病患者,评估以结局和患者为中心的管理模式。结果显示 PASI 从基线至 3 个月显著改善并维持至 9 个月,患者获益指数达标率高,科室依据是否超过预期 PBI 获得报酬。

要点

  • PASI 从基线至 3 个月平均降低 8.0,至 9 个月维持改善。
  • 3 个月和 9 个月 PBI≥1 的患者比例分别为 87.8% 和 95.1%。
  • 科室按实际 PBI 是否超过预期 PBI 获得报酬,人均 2721.1 DKK。

核心结论

  • 该基于价值的模式首次依据患者报告结局计算报酬,能预测预期 PBI 并按治疗目标是否达到或超过来支付。

研究设计与样本

  • 前瞻性非干预多中心研究,共纳入 49 例 PASI≥3 且正在启动或转换治疗的银屑病患者。
  • 患者在基线、3 个月和 9 个月接受评估,使用预设问卷计算患者获益指数 PBI。
  • 计算预期 PBI 并根据超重和吸烟等风险因素调整,科室报酬取决于实际 PBI 是否超过预期 PBI。

主要发现

  • 40 例(80%)完成全部三次访视,32.7% 为吸烟者,73.5% 为超重。
  • 基线平均 PASI 为 11.5(SD 9.1),至 3 个月平均降低 8.0(SD 9.2),p<0.001。
  • 3 个月至 9 个月平均进一步降低 0.1(SD 3.3),p=0.893。
  • 3 个月和 9 个月平均 PBI 分别为 2.5(SD 1.3)和 2.8(SD 1.1)。
  • 3 个月和 9 个月分别有 87.8% 和 95.1% 的患者达到 PBI≥1。

关键数值与推荐

  • 科室人均获得报酬 2721.1 DKK(SD 4472.8)。
  • 无、1 个或 2 个风险因素(吸烟和/或超重)的患者,科室人均报酬分别为 2428.6(SD 5089.5)、2636.6(SD 4471.3)和 3196.5(SD 4497.1)DKK。

临床怎么用

  • 可将基于患者报告结局的预期 PBI 用于银屑病以患者为中心的管理,并按是否达到或超过治疗目标进行报酬激励。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Little is known about the therapeutic benefits of a value-based healthcare model compared to a traditional activity-based incentive model in psoriasis (PsO). OBJECTIVES: This prospective non-interventional study evaluated an outcome-based, patient-centred management model for patients with PsO. METHODS: In total, 49 patients with a Psoriasis Area and Severity Index (PASI) ≥3 who were starting or switching between treatments were included. Patients were assessed at baseline, 3 and 9 months. The patient benefit index (PBI) was calculated using predefined questionnaires. An expected PBI was calculated and adjusted for risk factors known to complicate treatment, that is overweight and smoking. The model remunerated the department on whether the observed PBI exceeded the expected PBI to incentivize over-performance. RESULTS: In total, 40 patients (80%) completed all three visits; 32.7% were smokers and 73.5% were overweight. Mean PASI at baseline was 11.5 (SD 9.1); PASI improved significantly from baseline through 3 months: mean reduction, 8.0 (SD 9.2), p < 0.001 and was maintained until 9 months: mean further reduction, 0.1 (SD 3.3), p = 0.893. The mean PBI was 2.5 (SD 1.3) and 2.8 (SD 1.1) at 3 and 9 months, respectively. A PBI ≥1 was achieved by 87.8% at 3 and 95.1% at 9 months. Overall, the department was remunerated a mean 2721.1 DKK (SD 4472.8) per patient. In subgroup analysis, the department was remunerated a mean of, respectively, 2428.6 (SD 5089.5), 2636.6 (SD 4471.3) and 3196.5 (SD 4497.1) DKK for patients with none, 1 or 2 risk factors, that is smoking or/and overweight. CONCLUSIONS: The model evaluated herein is the first value-based model to calculate remuneration from patient reported outcomes and showed to successfully predict the expected PBI and remunerate treatment based on whether the expected treatment goal was met or exceeded. This can be utilized in the patient-centred management of PsO.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Nielsen VW, Johansen CB, Todberg T, et al. A value-based healthcare model for initiating and switching psoriasis therapies-Results from the prospective multicentre IMPROVE study. J Eur Acad Dermatol Venereol. 2023. PMID: 38095267. doi:10.1111/jdv.19690

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。